Pazopanib
- PDF / 141,020 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 20 Downloads / 148 Views
1
S
Skin and hair hypopigmentation: 3 case reports Three patients (1 female African American and 2 Caucasians) developed skin and hair hypopigmentation during treatment with pazopanib for thyroid cancer [ages and sex for the Caucasian patients not stated]. After receiving one to two cycles of pazopanib 800 mg/ daily, administered over a 28-day cycle, the patients developed hypopigmentation. Hypopigmentation peaked after six to ten cycles of pazopanib. The African American woman experienced her first episode of significant sunburn after initiating pazopanib. The degree of hypopigmentation observed in the Caucasian patients was consistent with that seen in albinism. Following dosage reduction, the woman’s hypopigmentation improved. An improvement in hypopigmentation, without dosage reduction, was noted for one of the Caucasian patients [outcome for the remaining patient not stated]. Sideras K, et al. Effect of pazopanib on hair and skin hypopigmentation: A series of three patients. 46th Annual Meeting of the American Society of Clinical Oncology : abstr. e13602, 8 Jun 2010. Available from: URL: http://www.asco.org 803024083 USA
0114-9954/10/1309-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 10 Jul 2010 No. 1309
Data Loading...
